KR20220097420A - 호흡기 세포융합 바이러스 (rsv) 감염 치료용 벤조디아제핀 유도체 - Google Patents

호흡기 세포융합 바이러스 (rsv) 감염 치료용 벤조디아제핀 유도체 Download PDF

Info

Publication number
KR20220097420A
KR20220097420A KR1020227017188A KR20227017188A KR20220097420A KR 20220097420 A KR20220097420 A KR 20220097420A KR 1020227017188 A KR1020227017188 A KR 1020227017188A KR 20227017188 A KR20227017188 A KR 20227017188A KR 20220097420 A KR20220097420 A KR 20220097420A
Authority
KR
South Korea
Prior art keywords
pyrazole
phenyl
oxo
carboxamide
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227017188A
Other languages
English (en)
Korean (ko)
Inventor
매튜 바렛
조지 스튜어트 코커릴
제임스 굿
크레이그 알렉스 에이버리
에드워드 제임스 코크레인
Original Assignee
리바이럴 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리바이럴 리미티드 filed Critical 리바이럴 리미티드
Publication of KR20220097420A publication Critical patent/KR20220097420A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020227017188A 2019-10-22 2020-10-22 호흡기 세포융합 바이러스 (rsv) 감염 치료용 벤조디아제핀 유도체 Ceased KR20220097420A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1915273.5 2019-10-22
GB201915273A GB201915273D0 (en) 2019-10-22 2019-10-22 Pharmaceutical compounds
PCT/GB2020/052658 WO2021079121A1 (en) 2019-10-22 2020-10-22 Benzodiazepine derivatives for treating a respiratory syncytial virus (rsv) infection

Publications (1)

Publication Number Publication Date
KR20220097420A true KR20220097420A (ko) 2022-07-07

Family

ID=68728299

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227017188A Ceased KR20220097420A (ko) 2019-10-22 2020-10-22 호흡기 세포융합 바이러스 (rsv) 감염 치료용 벤조디아제핀 유도체

Country Status (8)

Country Link
US (1) US20220409629A1 (cg-RX-API-DMAC7.html)
EP (1) EP4048665A1 (cg-RX-API-DMAC7.html)
JP (1) JP7667778B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220097420A (cg-RX-API-DMAC7.html)
CN (1) CN114761397B (cg-RX-API-DMAC7.html)
CA (1) CA3158169A1 (cg-RX-API-DMAC7.html)
GB (1) GB201915273D0 (cg-RX-API-DMAC7.html)
WO (1) WO2021079121A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201911944D0 (en) 2019-08-20 2019-10-02 Reviral Ltd Pharmaceutical compounds
GB201915932D0 (en) 2019-11-01 2019-12-18 Reviral Ltd Pharmaceutical compounds
GB202010409D0 (en) 2020-07-07 2020-08-19 Reviral Ltd Pharmaceutical compounds
WO2024252355A1 (en) 2023-06-08 2024-12-12 Pfizer Inc. Pediatric dosing regimens comprising a fusion inhibitor for the treatment of rsv
WO2025120500A1 (en) 2023-12-06 2025-06-12 Pfizer Inc. Benzodiazepine compounds as n-protein inhibitors
CN122580320A (zh) 2024-01-16 2026-08-14 辉瑞大药厂 作为n-蛋白抑制剂的苯二氮䓬吡唑甲酰胺类

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0314595A (pt) * 2002-09-20 2005-08-09 Arrow Therapeutics Ltd Uso de um derivado de benzodiazepina ou um sal farmaceuticamente aceitável deste, inalador ou nebulisador, produto, usos de um produto e de um composto ou sal farmaceuticamente aceitável deste, derivado de benzodiazepina, composto, e, composição farmacêutica
GB0221923D0 (en) * 2002-09-20 2002-10-30 Arrow Therapeutics Ltd Chemical compounds
GB0406280D0 (en) * 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Chemical compounds
GB0406282D0 (en) * 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds
US20070293482A1 (en) * 2004-03-19 2007-12-20 Novartis Pharmaceuticals Corporation Process for Preparing Benzodiazepines
GB0406279D0 (en) * 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds
CA2622592A1 (en) * 2005-09-19 2007-03-29 Arrow Therapeutics Limited Benzodiazepine derivatives for treating hepatitis c infection
US8871756B2 (en) * 2011-08-11 2014-10-28 Hoffmann-La Roche Inc. Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
GB201506448D0 (en) 2015-04-16 2015-06-03 Univ Durham An antimicrobial compound
MY197231A (en) * 2015-07-22 2023-06-06 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors
GB201613942D0 (en) 2016-08-15 2016-09-28 Univ Of Durham The An antimicrobial compound
WO2018129287A1 (en) 2017-01-06 2018-07-12 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as rsv inhibitors
WO2018226801A1 (en) 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as rsv inhibitors
WO2020190935A1 (en) * 2019-03-18 2020-09-24 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as rsv inhibitors
GB201911944D0 (en) * 2019-08-20 2019-10-02 Reviral Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
WO2021079121A1 (en) 2021-04-29
CN114761397B (zh) 2024-11-05
US20220409629A1 (en) 2022-12-29
GB201915273D0 (en) 2019-12-04
CN114761397A (zh) 2022-07-15
CA3158169A1 (en) 2021-04-29
JP7667778B2 (ja) 2025-04-23
JP2022553700A (ja) 2022-12-26
EP4048665A1 (en) 2022-08-31

Similar Documents

Publication Publication Date Title
JP7667778B2 (ja) 呼吸器合胞体ウイルス(rsv)感染症を治療するためのベンゾジアゼピン誘導体
DK2978752T3 (en) 6- (5-HYDROXY-1H-PYRAZOL-1-YL) NICOTINAMIDE DERIVATIVES AND THEIR USE AS PHD INHIBITORS
JP7667779B2 (ja) 医薬化合物
JP2020019812A (ja) Lsd1阻害剤としてのシクロプロピルアミン類
KR20220075317A (ko) 약학적 화합물
JP6695334B2 (ja) 呼吸器合胞体ウイルス感染症(rsv)の治療又は予防のためのスピロインドリン
JP2023539985A (ja) 呼吸器合胞体ウイルス感染症の治療に有用なベンゾジアゼピン誘導体
WO2022008912A1 (en) Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection
US11078189B2 (en) Pharmaceutical compounds
ES2905650T3 (es) Compuestos farmacéuticos
WO2022180397A1 (en) Benzodiazepines for treating or preventing respiratory syncytial virus infection
CN105899504A (zh) 用于治疗和预防呼吸道合胞病毒感染的咪唑化合物
KR102873079B1 (ko) Rna 바이러스 감염 치료를 위한 아릴-n-아릴 유도체
CA3273670A1 (en) Inhibitors of .alpha.-hemolysin of staphylococcus aureus
HK1217701B (en) 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
HK1228383A1 (en) Imidazoles for the treatment and prophylaxis of respiratory syncytial virus infection

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601